Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U et al. Cyclosporine A and mycofenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical sibling. Bone Marrow Transplant 2005; 35: 1089–1093.

    Article  CAS  Google Scholar 

  2. Niederwieser D, Maris M, Schizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total irradiation (TBI) and fludarabin followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycofenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological disease. Blood 2003; 101: 1620–1629.

    Article  CAS  Google Scholar 

  3. Bornhauser M, Schuler U, Porksen G, Naumann R, Geissler G, Thiede C et al. Mycofenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499–509.

    Article  CAS  Google Scholar 

  4. Pohlreich D, Vitek A, Valkova V, Markova M, Maalouf J, Kouba M et al. Cyclosporine-methotrexate versus cyclosporine-mycophenolate in the prevention of GvHD in stem cell transplantation using myeloablative regimens. Bone Marrow Transplant 2005; 35 (Suppl 2): 149.

    Google Scholar 

  5. Bolwell BJ, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporin+short course methotrexate to cyclosporine+mycophenolate for GVHD prophylaxis in ablative allogeneic BMT. Bone Marrow Transplant 2004; 34: 621–625.

    Article  CAS  Google Scholar 

  6. Kiehl MG, Schafer-Eckart K, Kroger M, Bornhauser M, Basara N, Blau IW et al. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host-disease in stem cell transplant recipients. Transplant Proc 2002; 34: 2922–2924.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D Pohlreich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pohlreich, D., Vitek, A., Maalouf, J. et al. Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens. Bone Marrow Transplant 37, 235–236 (2006). https://doi.org/10.1038/sj.bmt.1705227

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705227

This article is cited by

Search

Quick links